We are witnessing the development of new treatment modalities for primary brain tumors. An area under intense investigation is the use of small molecules targeting intracellular signaling pathways that interfere with growth, invasion, and metastasis of high-grade gliomas.
Methods
We review clinical trials of small molecules in adults with brain tumors. This search included electronic databases, specialty journals, textbooks, proceedings, and Web sites of the National Cancer Institute and other cooperative brain tumor groups in Europe and the United States.
Results
Several drugs with the ability to down-regulate the growth and invasion of malignant gliomas are at various stages of testing. Most of these focus on interfering with oncogenic and tumor survival pathways. Examples include inhibitors of tyrosine kinases, farnesyltransferases, and matrix metalloproteinases. These molecules are at different stages of testing, and a conclusive picture of which drug is most effective, either alone or in combination, needs better definition. The metalloproteinase inhibitor marimastat with temozolomide has given the best results to date in phase II trials, increasing the rate of 6-month progression-free survival for recurrent glioblastoma multiforme and anaplastic gliomas.
Conclusions
As our understanding of the biology of gliomas increases and new drugs targeting specific molecular pathways enter well-designed cooperative trials, the control and prognosis of these tumors should improve.
References
1.
StewartL.A.. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.Lancet.2002; 359: 1011–1018.
2.
HanahanD., WeinbergR.A.. The hallmarks of cancer.Cell.2000; 100: 57–70.
WorkmanP.. Signal transduction pathways: a goldmine for therapeutic targets. In: SebtiS.M., HamiltonA.D., eds. Farnesyltransferase Inhibitors in Cancer Therapy.Totowa, New Jersey: Humana Press;2001: 1–19.
9.
ThiesingJ.T., Ohno-JonesS., KolibabaK.S.. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.Blood.2000; 96: 3195–3199.
10.
TraxlerP., BoldG., BuchdungerE.. Tyrosine kinase inhibitors: from rational design to clinical trials.Med Res Rev.2001; 21: 499–512.
11.
MauroM.J., DrukerB.J.. STI571: targeting BCR-ABL as therapy for CML.Oncologist.2001; 6: 233–238.
12.
MauroM.J., O'DwyerM., HeinrichM.C.. STI571: a paradigm of new agents for cancer therapeutics.J Clin Oncol.2002; 20: 325–34.
13.
KilicT., AlbertaJ.A., ZdunekP.R.. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.Cancer Res.2000; 60: 5143–5150.
14.
Phase I-II trial of STI571 in patients with recurrent malignant gliomas or meningiomas. Available at: http://www.nabtc.org/PUB-NABTC99-08.htm. Accessed February 12, 2003.
RaymondE., FaivreS., ArmandJ.P.. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.Drugs.2000; 60: 15–23.
18.
SwaislandH., LaightA., StaffordL.. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.Clin Pharmacokinet.2001; 40: 297–306.
19.
TortoraG., CiardielloF.. Protein kinase A as target for novel integrated strategies of cancer therapy.Ann N Y Acad Sci.2002; 968: 139–147.
20.
RansonM., HammondL.A., FerryD.. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.J Clin Oncol.2002; 20: 2240–2250.
HerbstR.S.. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.Expert Opin Investig Drugs.2002; 11: 837–849.
23.
BaselgaJ., AverbuchS.D.. ZD1839 (“Iressa”) as an anticancer agent.Drugs.2000; 60: 33–42.
24.
BarkerA.J., GibsonK.H., GrundyW.. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.Bioorg Med Chem Lett.2001; 11: 1911–1914.
25.
AndersonN.G., AhmadT., ChanK.. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.Int J Cancer.2001; 94: 774–782.
26.
AlbanellJ., Codony-ServatJ., RojoF.. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.Cancer Res.2001; 61: 6500–6510.
27.
RabenD., HelfrichB.A., ChanD.. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.Semin Oncol.2002; 29: 37–46.
28.
SirotnakF.M., ZakowskiM.F., MillerV.A.. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.Clin Cancer Res.2000; 6: 4885–4892.
29.
WilliamsK.J., TelferB.A., StratfordI.J.. ZD1839 (“Iressa”), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.Br J Cancer.2002; 86: 1157–1161.
30.
AlbanellJ., RojoF., AverbuchS.. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.J Clin Oncol.2002; 20: 110–124.
31.
GilmoreA.P., ValentijnA.J., WangP.. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and trans-activation by insulin-like growth factor receptor.J Biol Chem.2002; 277: 27643–2750.
SmithJ.S., TachibanaI., PasseS.M.. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.J Natl Cancer Inst.2001; 93: 1246–1256.
ZD1839 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study With a Phase I Component for Patients Receiving EIAEDs. Available at: http://www.nabtc.org/PUB-NABTC00-01.htm. Accessed February 12, 2003.
37.
A Phase I Study of ZD1839 and Temozolomide for the Treatment of Malignant Gliomas. Available at: http://www.nabtc.org/PUB-NABTC01-02.htm. Accessed February 12, 2003.
38.
DyG.K., AdjeiA.A.. Novel targets for lung cancer therapy: part I.J Clin Oncol.2002; 20: 2881–2894.
39.
HidalgoM., SiuL.L., NemunaitisJ.. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.J Clin Oncol.2001; 19: 3267–3279.
40.
NormanP.. OSI-774 OSI pharmaceuticals.Curr Opin Investig Drugs.2001; 2: 298–304.
41.
StamosJ., SliwkowskiM.X., EigenbrotC.. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.J Biol Chem.2002; 277: 46265–46272.
42.
PradosM.. A phase I study of OSI-774 + temozolomide in patients for recurrent or stable malignant glioma. Houston, Texas. (Personal communication, 2002.)
43.
BrunnG.J., WilliamsJ., SabersC.. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.EMBO J.1996; 15: 5256–5267.
44.
DudkinL., DillingM.B., CheshireP.J.. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.Clin Cancer Res.2001; 7: 1758–1764.
45.
GarberK.. Rapamycin's resurrection: a new way to target the cancer cell cycle.J Natl Cancer Inst.2001; 93: 1517–1519.
46.
HidalgoM., RowinskyE.K.. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.Oncogene.2000; 19: 6680–6686.
HuangS., HoughtonP.J.. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.Curr Opin Investig Drugs.2002; 3: 295–304.
49.
OwaT., YoshinoH., YoshimatsuK.. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.Curr Med Chem.2001; 8: 1487–1503.
50.
ShiY., HsuJ.H., HuL.. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.J Biol Chem.2002; 277: 15712–15720.
51.
YuK., Toral-BarzaL., DiscafaniC.. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.Endocr Relat Cancer.2001; 8: 249–258.
52.
GeoergerB., KerrK., TangC.B.. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.Cancer Res.2001; 61: 1527–1532.
53.
NeshatM.S., MellinghoffI.K., TranC.. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.Proc Natl Acad Sci U S A.2001; 98: 10314–10319.
54.
PodsypaninaK., LeeR.T., PolitisC.. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.Proc Natl Acad Sci U S A.2001; 98: 10320–10325.
ChangS., WenP.Y., GreenbergH.. Phase I study of CCI-779 in patients with recurrent malignant glioma (MG) on enzyme inducing antiepileptic drugs (EIAEDs).Neuro-oncol.2002; 4: 367.
58.
A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme. Available at: http://ncctg.mayo.edu/protocols/N997B. Accessed February 12, 2003.
59.
BucknerJ.C., PradosM., RowinskyE.K.. A phase I study of the safety, tolerability, and pharmacokinetics of intravenous CCI-779 given once daily for 5 days every two weeks to patients with CNS tumors.Neuro-oncol.2002; 4: 365.
60.
SchulerW., SedraniR., CottensS.. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.Transplantation.1997; 64: 36–42.
61.
SchuurmanH.J., CottensS., FuchsS.. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine.Transplantation.1997; 64: 32–35.
62.
SedraniR., CottensS., KallenJ.. Chemical modification of rapamycin: the discovery of SDZ RAD.Transplant Proc.1998; 30: 2192–2194.
63.
HaubitzM., BrunkhorstR.. Influence of a novel rapamycin analog SDZ RAD on endothelial tissue factor and adhesion molecule expression.Transplant Proc.2002; 34: 1124–1126.
64.
SDZ RAD.Rapamycin SDZ.Drugs R D.1999; 1: 97–99.
65.
KarpJ.E., KaufmannS.H., AdjeiA.A.. Current status of clinical trials of farnesyltransferase inhibitors.Curr Opin Oncol.2001; 13: 470–476.
66.
PatnaikA., RowinskyE.K.. Early clinical experience with farnesyl protein transferase inhibitors. In: SebtiS.M., HamiltonA.D., eds. Farnesyltransferase Inhibitors in Cancer Therapy.Totowa, New Jersey: Humana Press;2000: 233–249.
GlassT.L., LiuT.J., YungW.K.. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.Neuro-oncol.2000; 2: 151–158.
69.
ShiB., YaremkoB., HajianG.. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.Cancer Chemother Pharmacol.2000; 46: 387–393.
70.
HooverR.R., MahonF.X., MeloJ.V.. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.Blood.2002; 100: 1068–1071.
71.
AdjeiA.A., DavisJ.N., BruzekL.M.. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.Clin Cancer Res.2001; 7: 1438–1445.
72.
WangH., MaurerB.J., ReynoldsC.P.. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.Cancer Res.2001; 61: 5102–5105.
DelmasC., HeliezC., Cohen-JonathanE.. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.Int J Cancer.2002; 100: 43–48.
75.
ZujewskiJ., HorakI.D., BolC.J.. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.J Clin Oncol.2000; 18: 927–941.
76.
CrulM., de KlerkG.J., SwartM.. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.J Clin Oncol.2002; 20: 2726–2735.
77.
A Phase I and II Trial of R115777 in Patients with Recurrent Malignant Gliomas. Available at: http://www.nabtc.org/PUB-NABTC99-01.htm. Accessed February 12, 2003.
78.
CloughesyT.F., KuhnJ., WenP.. Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report.Proc Annu Meet Am Soc Clin Oncol.2002; 21: 317. Abstract.
79.
RosenL.S.. Angiogenesis inhibition in solid tumors.Cancer J.2001; 7: S120–S128.
80.
VajkoczyP., MengerM.D., VollmarB.. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.Neoplasia.1999; 1: 31–41.
81.
ShepherdF.A.. Angiogenesis inhibitors in the treatment of lung cancer.Lung Cancer.2001; 34: S81–S89.
82.
ShaheenR.M., DavisD.W., LiuW.. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.Cancer Res.1999; 59: 5412–5416.
83.
MendelD.B., SchreckR.E., WestD.C.. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.Clin Cancer Res.2000; 6: 4848–4858.
84.
MendelD.B., LairdA.D., SmolichB.D.. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.Anticancer Drug Des.2000; 15: 29–41.
85.
A Phase I and II Trial of SU5416 in Patients with Recurrent High Grade Astrocytomas or Mixed Gliomas. Available at: http://www.nabtc.org/PUB-NABTC99-02.htm. Accessed February 12, 2003.
86.
WoodJ.M., BoldG., BuchdungerE.. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.Cancer Res.2000; 60: 2178–2189.
87.
DrevsJ., HofmannI., HugenschmidtH.. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.Cancer Res.2000; 60: 4819–4824.
88.
BoldG., AltmannK.H., FreiJ.. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.J Med Chem.2000; 43: 2310–2323.
89.
HessC., VuongV., HegyiI.. Effect of VEGF receptor inhibitor PTK787/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth.Br J Cancer.2001; 85: 2010–2016.
A phase IB, open-label, 2-arm dose-escalation study of PTK787/ZK 222584 in combination with single agent chemotherapy, either temozolomide (arm 1) or lomustine (arm 2) in patients with glioblastoma multiforme (GBM). Available at: http://utm-notes-db2.mdacc.tmc.edu/mdacc/ClinicalTrialsWP.nsf/Index/DM01-401. Accessed February 12, 2003.
92.
YungW.K., FriedmanH., JacksonE.. A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma.Proc Annu Meet Am Soc Clin Oncol.2002; 21: 315. Abstract.
93.
ReardonD.A., FriedmanH., YungW.K.. A phase I trial of temodar plus PTK787/ZK222584 (PTK/ZK), a novel oral VEGFR TK inhibitor, for patients with recurrent glioblastoma.Neuro-oncol.2002; 4: 375.
94.
WebbC.P., Vande WoudeG.F.. Genes that regulate metastasis and angiogenesis.J Neurooncol.2000; 50: 71–87.
95.
WaryK.K., MainieroF., IsakoffS.J.. The adaptor protein Shc couples a class of integrins to the control of cell cycle progression.Cell.1996; 87: 733–743.
OktayM., WaryK.K., DansM.. Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle.J Cell Biol.1999; 145: 1461–1469.
98.
BarberisL., WaryK.K., FiucciG.. Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK.J Biol Chem.2000; 275: 36532–36540.
99.
MettouchiA., KleinS., GuoW.. Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle.Mol Cell.2001; 8: 115–127.
100.
Erdreich-EpsteinA., ShimadaH., GroshenS.. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.Cancer Res.2000; 60: 712–721.
101.
D'AmatoR.J., LoughnanM.S., FlynnE.. Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci U S A.1994; 91: 4082–4085.
102.
CalabreseL., FleischerA.B.. Thalidomide: current and potential clinical applications.Am J Med.2000; 108: 487–495.
103.
CohenM.H.. Thalidomide in the treatment of high-grade gliomas.J Clin Oncol.2000; 18: 3453.
104.
AdlardJ.W.. Thalidomide in the treatment of cancer.Anticancer Drugs.2000; 11: 787–791.
AmatoR.J.. Thalidomide: an antineoplastic agent.Curr Oncol Rep.2002; 4: 56–62.
109.
MeierhoferC., DunzendorferS., WiedermannC.J.. Theoretical basis for the activity of thalidomide.BioDrugs.2001; 15: 681–703.
110.
ZhouS., KestellP., TingleM.D.. Thalidomide in cancer treatment: a potential role in the elderly?Drugs Aging.2002; 19: 85–100.
111.
FineH.A., FiggW.D., JaeckleK.. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.J Clin Oncol.2000; 18: 708–715.
112.
MarxG.M., PavlakisN., McCowattS.. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.J Neurooncol.2001; 54: 31–38.
113.
ShortS.C., TraishD., DoweA.. Thalidomide as an anti-angiogenic agent in relapsed gliomas.J Neurooncol.2001; 51: 41–45.
114.
GrovesM.D., Tremont-LukatsI.W., ConradC.. A phase II trial of temozolomide plus thalidomide (NABTC 99-04) for recurrent glioblastoma multiforme.Neuro-Oncol.2002; 4: S41.
115.
HwuW.J., KrownS.E., PanageasK.S.. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.J Clin Oncol.2002; 20: 2610–2615.
116.
KammW., JonczykA., JungT.. Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2).Eur J Pharm Sci.2000; 10: 205–214.
117.
MacDonaldT.J., TagaT., ShimadaH.. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.Neurosurgery.2001; 48: 151–157.
118.
HerbstR.S., HidalgoM., PiersonA.S.. Angiogenesis inhibitors in clinical development for lung cancer.Semin Oncol.2002; 29: 66–77.
119.
TagaT., SuzukiA., Gonzalez-GomezI.. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.Int J Cancer.2002; 98: 690–697.
NaborsL.B., RosenfeldS.S., MikkelsenT.. A phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas.Neuro-oncol.2002; 4: 373.
122.
EgidyG., EberlL.P., ValdenaireO.. The endothelin system in human glioblastoma.Lab Invest.2000; 80: 1681–1689.
123.
WessaleJ.L., AdlerA.L., NovosadE.I.. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.Clin Sci (Lond).2002; 103: 112S–117S.
124.
SamaraE., DuttaS., CaoG.. Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist.J Clin Pharmacol.2001; 41: 397–403.
125.
GosselinM., GouletS., Wu-WongJ.R.. Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity.Clin Sci (Lond).2002; 103: 367S–70S.
126.
CarducciM.A., NelsonJ.B., BowlingM.K.. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.J Clin Oncol.2002; 20: 2171–2180.
127.
AsanoT., AoyagiM., HirakawaK.. Effect of endothelin-1 as growth factor on a human glioma cell line; its characteristic promotion of DNA synthesis.J Neurooncol.1994; 18: 1–7.
128.
KawanabeY., HashimotoN., MasakiT.. Effects of extracellular Ca2+ influx on endothelin-1-induced intracellular mitogenic cascades in C6 glioma cells.Eur J Pharmacol.2002; 435: 119–123.
129.
StilesJ.D., OstrowP.T., BalosL.L.. Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas.J Neuropathol Exp Neurol.1997; 56: 435–439.
130.
Atrasentan prolongs time to progression in prostate cancer patients.Oncology (Huntingt).2001; 15: 833–917.
ZhangW., SakaiN., YamadaH.. Endothelin-1 induces intracellular calcium rise and inositol 1,4,5-trisphosphate formation in cultured rat and human glioma cells.Neurosci Lett.1990; 112: 199–204.
133.
ZhangW., SakaiN., FuT.. Diacylglycerol formation and DNA synthesis in endothelin-stimulated rat C6 glioma cells: the possible role of phosphatidylcholine breakdown.Neurosci Lett.1991; 123: 164–166.
134.
CouraudP.O., Durieu-TrautmannO., NguyenD.L.. Functional endothelin-1 receptors in rat astrocytoma C6.Eur J Pharmacol.1991; 206: 191–198.
135.
JaeH.S., WinnM., von GeldernT.W.. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.J Med Chem.2001; 44: 3978–3984.
HidalgoM., EckhardtS.G.. Development of matrix metalloproteinase inhibitors in cancer therapy.J Natl Cancer Inst.2001; 93: 178–193.
138.
DenisL.J., VerweijJ.. Matrix metalloproteinase inhibitors: present achievements and future prospects.Invest New Drugs.1997; 15: 175–185.
139.
DrummondA.H., BeckettP., BrownP.D.. Preclinical and clinical studies of MMP inhibitors in cancer.Ann N Y Acad Sci.1999; 878: 228–235.
140.
HeathE.I., GrochowL.B.. Clinical potential of matrix metalloprotease inhibitors in cancer therapy.Drugs.2000; 59: 1043–55.
141.
MillarA.W., BrownP.D., MooreJ.. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.Br J Clin Pharmacol.1998; 45: 21–26.
142.
RasmussenH.S., McCannP.P.. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.Pharmacol Ther.1997; 75: 69–75.
143.
GrovesM.D., PuduvalliV.K., HessK.R.. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.J Clin Oncol.2002; 20: 1383–1388.
144.
GrovesM.D., PuduvalliV.K., GilbertM.R.. A phase II study of temozolomide plus marimastat for recurrent anaplastic glioma (AG).Neuro-oncol.2002; 4: S369.
145.
NewP., MikkelsenT., PhuphanichS.. A phase I/II study of COL-3 administered on a continuous oral schedule in patients with recurrent high grade glioma. Preliminary results of the NABTT 9809 clinical trial.Neuro-oncol.2002; 4: 373.
146.
PriceA., ShiQ., MorrisD.. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.Clin Cancer Res.1999; 5: 845–854.
ZuckerS., CaoJ., ChenW.T.. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.Oncogene.2000; 19: 6642–6650.
149.
ScatenaR.. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor: a novel pharmacological approach for tissue remodeling-related diseases.Expert Opin Investig Drugs.2000; 9: 2159–2165.
150.
LevineP.A., PhuphanichS., GlantzM.J.. Randomized phase II study of temozolomide (TMZ) with and without the metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy.Proc Annu Meet Am Soc Clin Oncol.2002; 21: 100. Abstract.
151.
AdamsJ.. Proteasome inhibition in cancer: development of PS-341.Semin Oncol.2001; 28: 613–619.
152.
AdamsJ.. Proteasome inhibition: a novel approach to cancer therapy.Trends Mol Med.2002; 8: S49–S54.
153.
AdamsJ.. Development of the proteasome inhibitor PS-341.Oncologist.2002; 7: 9–16.
TeicherB.A., AraG., HerbstR.. The proteasome inhibitor PS-341 in cancer therapy.Clin Cancer Res.1999; 5: 2638–2645.
156.
LingY.H., LiebesL., NgB.. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.Mol Cancer Ther.2002; 1: 841–849.
IshizakiY., MoritaI., MurotaS.. Arachidonic acid metabolism in cultured astrocytes from rat embryo and in C6 glioma cells.Brain Res.1989; 494: 138–142.
159.
BlomgrenH., Kling-AnderssonG.. Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids.Anticancer Res.1992; 12: 981–986.
160.
KurzelF., HagelC., ZapfS.. Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells.Acta Neurochir (Wien).2002; 144: 71–87.
161.
GátiI., BergstromM., WesterbergG.. Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids.Eur J Cancer.1990; 26: 802–807.
162.
GátiI., BergstromM., CsokaK.. Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines.Prostaglandins Leukot Essent Fatty Acids.1990; 40: 117–124.
163.
PortnowJ., SulemanS., GrossmanS.A.. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas.Neuro-oncol.2002; 4: 22–25.
164.
KingJ.G.Jr., KhaliliK.. Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen.Oncogene.2001; 20: 6864–6870.
165.
RistimakiA., HonkanenN., JankalaH.. Expression of cyclooxygenase-2 in human gastric carcinoma.Cancer Res.1997; 57: 1276–1280.
166.
EberhartC.E., CoffeyR.J., RadhikaA.. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.Gastroenterology.1994; 107: 1183–1188.
167.
ShonoT., TofilonP.J., BrunerJ.M.. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.Cancer Res.2001; 61: 4375–4381.
168.
JokiT., HeeseO., NikasD.C.. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.Cancer Res.2000; 60: 4926–4931.
LangF.F., GilbertM.R., PuduvalliV.K.. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.Neuro-oncol.2002; 4: 268–277.
